Open access
Aug 2026
The CA19-9 glycan is a viable target for CAR T cell therapy in pancreatic and other solid tumors.
BACKGROUND & AIMS Chimeric antigen receptor (CAR) T cell therapy for pancreatic ductal adenocarcinoma (PDAC) has been challenging, in part due to the paucity of tumor-specific cell-surface targets. Here, we explored the design feasibility and anti-tumor efficacy of CAR T cells recognizing the CA19-9 glycan, a tumor ant...
Fei-Yan Mo, Austin L. Good, Jayne C. McDevitt et al.
· Gastroenterology · 0 citations